Home    Back

 Target Gene/Pathway 

   e.g. "Sirolimus", "Adalimumab", "MAP2K"

A    B    C    D    E    F    G    H     I     J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    other

7 / 275 pathways found* Show info (disease name, etc.) on mouse-over.
 No.   KEGG PATHWAY * 
 On map, Yellow: Drug target, Red: Disease-related 		  KEGG GENES * 
 [Number of genes] 		  KEGG DRUG *   DrugBank   Disease ID * 
 [Number of diseases] 
 1  GABAergic synapse 
 16 genes, 1 drug (DrugBank), 3 diseases shown 		  [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   D04300   Ganaxolone   [3] 145, 152, 206 
 2  Morphine addiction 
 16 genes, 1 drug (DrugBank), 3 diseases shown 		  [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   D04300   Ganaxolone   [3] 145, 152, 206 
 3  Neuroactive ligand-receptor interaction 
 16 genes, 1 drug (DrugBank), 3 diseases shown 		  [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   D04300   Ganaxolone   [3] 145, 152, 206 
 4  Nicotine addiction 
 16 genes, 1 drug (DrugBank), 3 diseases shown 		  [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   D04300   Ganaxolone   [3] 145, 152, 206 
 5  Retrograde endocannabinoid signaling 
 16 genes, 1 drug (DrugBank), 3 diseases shown 		  [16] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   D04300   Ganaxolone   [3] 145, 152, 206 
 6  Serotonergic synapse 
 3 genes, 1 drug (DrugBank), 3 diseases shown 		  [3] GABRB1, GABRB2, GABRB3   D04300   Ganaxolone   [3] 145, 152, 206 
 7  Taste transduction 
 6 genes, 1 drug (DrugBank), 3 diseases shown 		  [6] GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6   D04300   Ganaxolone   [3] 145, 152, 206 

Back to top